Curative Biotechnology Inc (CUBT)

$0.01 0.00 (-13.92%)
Market Cap 6.96M
Revenue (ttm) 0.00
Net Income (ttm) -5.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 245,100
Avg Vol 170,124
Day's Range N/A - N/A
Shares Out 1.02B
Stochastic %K 10%
Beta 1.40
Analysts Strong Buy
Price Target N/A

Company Profile

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth a...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 907 8990
Address:
3801 PGA Blvd, Suite 600, Palm Beach Gardens, United States
Austero
Austero Mar. 29 at 10:22 AM
https://curativebiotech.com Research and pilot clinical studies suggest that adding ($CUBT ) IMT504 as an adjuvant can significantly enhance the effectiveness of the $SNY SanofI Pasteur Vero rabies vaccine (Verorab®), particularly by allowing for a lower dose of antigen. Benefits of IMT504 as an Adjuvant Dose Sparing: Studies in both rats and humans showed that a vaccine diluted to 1/5 of its original strength, when combined with IMT504, remained highly effective. In rat models, protection was maintained even at dilutions as high as 1/625. Faster & Higher Antibody Response: Human volunteers receiving the IMT504-adjuvanted diluted vaccine developed protective antibody levels (≥0.5 IU/ml) faster than those receiving non-adjuvanted versions. Potential for Fewer Injections https://ri.conicet.gov.ar/bitstream/handle/11336/67890/CONICET_Digital_Nro.f426a143-8c88-4773-941b-cfdd6658ec42_A.pdf?sequence=2&isAllowed=y
1 · Reply
Austero
Austero Mar. 28 at 10:40 PM
$CUBT $12-54 SP potential!
0 · Reply
Austero
Austero Mar. 27 at 1:12 PM
$CUBT Analyze this chart. Thoughts on their strategy. Looks like their next 48-60 month vision.
1 · Reply
longtermopportunity
longtermopportunity Mar. 26 at 3:46 PM
$CUBT the fact they only did a 150-1 split tells me they have upside from 1.00 and this is undervalued . Let’s see
0 · Reply
Austero
Austero Mar. 26 at 3:30 AM
$CUBT Phase 1 Valuation potential is a range of $12 to $54 per share.
0 · Reply
Austero
Austero Mar. 24 at 6:00 PM
$CUBT Dual Human and Canine efforts. Phase 1 success is very likely due to metformin vast safety profile. Phase 1 itself could be its sole inflection point.
0 · Reply
Austero
Austero Mar. 24 at 5:58 PM
$CUBT https://curativebiotech.com/k9-retinal-program
0 · Reply
longtermopportunity
longtermopportunity Mar. 24 at 3:09 PM
$CUBT real share price is 1.00+ . Will correct itself when a buy comes in
1 · Reply
Billy_D
Billy_D Mar. 24 at 4:03 AM
$CUBT
0 · Reply
rednod6
rednod6 Mar. 23 at 1:42 PM
$CUBT Curative Biotechnology Announces Reverse Stock Split and https://share.google/svOOuxbY1vWD6xAUs
0 · Reply
Latest News on CUBT
No data available.
Austero
Austero Mar. 29 at 10:22 AM
https://curativebiotech.com Research and pilot clinical studies suggest that adding ($CUBT ) IMT504 as an adjuvant can significantly enhance the effectiveness of the $SNY SanofI Pasteur Vero rabies vaccine (Verorab®), particularly by allowing for a lower dose of antigen. Benefits of IMT504 as an Adjuvant Dose Sparing: Studies in both rats and humans showed that a vaccine diluted to 1/5 of its original strength, when combined with IMT504, remained highly effective. In rat models, protection was maintained even at dilutions as high as 1/625. Faster & Higher Antibody Response: Human volunteers receiving the IMT504-adjuvanted diluted vaccine developed protective antibody levels (≥0.5 IU/ml) faster than those receiving non-adjuvanted versions. Potential for Fewer Injections https://ri.conicet.gov.ar/bitstream/handle/11336/67890/CONICET_Digital_Nro.f426a143-8c88-4773-941b-cfdd6658ec42_A.pdf?sequence=2&isAllowed=y
1 · Reply
Austero
Austero Mar. 28 at 10:40 PM
$CUBT $12-54 SP potential!
0 · Reply
Austero
Austero Mar. 27 at 1:12 PM
$CUBT Analyze this chart. Thoughts on their strategy. Looks like their next 48-60 month vision.
1 · Reply
longtermopportunity
longtermopportunity Mar. 26 at 3:46 PM
$CUBT the fact they only did a 150-1 split tells me they have upside from 1.00 and this is undervalued . Let’s see
0 · Reply
Austero
Austero Mar. 26 at 3:30 AM
$CUBT Phase 1 Valuation potential is a range of $12 to $54 per share.
0 · Reply
Austero
Austero Mar. 24 at 6:00 PM
$CUBT Dual Human and Canine efforts. Phase 1 success is very likely due to metformin vast safety profile. Phase 1 itself could be its sole inflection point.
0 · Reply
Austero
Austero Mar. 24 at 5:58 PM
$CUBT https://curativebiotech.com/k9-retinal-program
0 · Reply
longtermopportunity
longtermopportunity Mar. 24 at 3:09 PM
$CUBT real share price is 1.00+ . Will correct itself when a buy comes in
1 · Reply
Billy_D
Billy_D Mar. 24 at 4:03 AM
$CUBT
0 · Reply
rednod6
rednod6 Mar. 23 at 1:42 PM
$CUBT Curative Biotechnology Announces Reverse Stock Split and https://share.google/svOOuxbY1vWD6xAUs
0 · Reply
rednod6
rednod6 Mar. 20 at 11:56 PM
$CUBT https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
1 · Reply
Chinga77
Chinga77 Feb. 18 at 8:03 PM
$CUBT amazing over 1 billion shares outstanding this company has been a pile of trash orchestrated by a bunch of Js to defraud and take investors money
0 · Reply
Toadzilla
Toadzilla Feb. 6 at 2:21 AM
$CUBT when is the rs?
0 · Reply
Fjam
Fjam Jan. 29 at 1:50 PM
$BCDS yesterday's tape was interesting. Lots of DOUBLE PRINTS. I was in several tickers with lots of double prints and they all RAN HARD. $JADA $DBMM $CTYX now CUBT $DBMM was slightly different because of their situation at the time and it ran 10,000 percent $JADA ran from .04 to .70 $CTYX now $CUBT ran from .005 to .19 Here is an OLD TWEET from me saying the same. https://x.com/i/status/1664130709722628098
0 · Reply
Chinga77
Chinga77 Jan. 27 at 11:24 PM
$CUBT this stock is always been a pile of crap that’s why the investor relations guy Steve Chiswick pretended to be somebody else just your every day average investor for two years on investor hub until I called him out and told everyone who he was. You had three flight working with them this is a typical company who takes care of their own as in a specific group that hails from a land far away
0 · Reply
Finanz
Finanz Jan. 24 at 2:36 AM
$CUBT https://finance.yahoo.com/news/curative-biotechnology-announces-canadian-patent-134500058.htmle Rare to see a sub penny stock get patents. Proves their is a pulse here.
0 · Reply
Austero
Austero Jan. 23 at 10:07 PM
$CUBT https://finance.yahoo.com/news/curative-biotechnology-announces-canadian-patent-134500058.html
0 · Reply
longtermopportunity
longtermopportunity Jan. 23 at 8:25 PM
$CUBT combine up today something up ? $NWBO good times are coming
1 · Reply
rednod6
rednod6 Jan. 23 at 2:11 PM
$CUBT https://investorshub.advfn.com/stock-market/USOTC/curative-biotechnology-id-CUBT/stock-news/97677722/curative-biotechnology-announces-canadian-patent-a
0 · Reply
Borse55
Borse55 Jan. 8 at 12:19 AM
$CUBT Paul M MichaelsPaul M Michaels Executive Chairman, co-CEO & President Curative Biotechnology, Inc. As we step into the New Year and look ahead to a productive 2026, Curative Biotech remains focused on thoughtful growth, seeking programs that align with our model. We deliberately pursue indications with significant unmet medical need, guided by a patient-first mindset at every stage of development. Whether human or canine, our objective is to advance programs to meaningful value-creating inflection points that truly matter for patients. In some cases, the final stages of development and commercialization are best executed by larger partners with the scale, infrastructure, and global expertise to bring therapies to patients efficiently and responsibly. In those hands, programs are well positioned to succeed. Our company is built on reaching those critical inflection points we can monetize—while ensuring each program ultimately resides with the partner best equipped.
0 · Reply
rednod6
rednod6 Jan. 7 at 9:22 PM
$CUBT https://www.linkedin.com/posts/paul-m-michaels_as-we-step-into-the-new-year-and-look-ahead-activity-7414669197936406528-AwR-?utm_source=share&utm_medium=member_android&rcm=ACoAAC5SabIBtz_AOYFB3farfCgsByhy2x4zCeg
1 · Reply
Smcg621
Smcg621 Jan. 4 at 12:42 PM
$CUBT curious if this is true, new rules state that companies are not allowed to execute reverse splits in order to gain compliance? Does that affect CUBT? Or is that strictly an uplisting tactic they are trying to use?
1 · Reply